Back Back
Cell No. : Cell Name
RCB1145 : 32D  update : 2024/01/17
CommentIL-3 dependent cells from Friend leukemia virus-infected mouse bone marrow.
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (
Basic information Depositor Todokoro, Kazuo
Year of deposit 1995
Animal _mouse < Mammals
Strain name C3H/HeJ
Tissue bone marrow
Disease name Friend leukemia
Classification transformed
Lifespan infinite
Morphology lymphocyte-like
Cellosaurus(Expasy) CVCL_0118
deposit info
lot info
Medium Medium List
Culture type Suspension cells
Culture method 浮遊細胞の培養に関する一般的な注意(Japanese)
Culture medium RPMI1640 + 10% FBS + 10U/ml rmouse IL-3
Antibiotics Free
Passage method dilution
Culture information Passage ratio 1 : 10-20 split
SC frequency Subculture : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
SSLP(mouse) OK
Isozyme LD, NP
deposit info
lot info
Reference information Reference 6
User's Publication 8

To topTop
1980  Reisbach G, Ellwart J, Dormer P  Lactate production and amino acid incorporation in interleukin 3-dependent, factor-deprived hemopoietic murine cell lines.  Exp Cell Res  1990  190:175-8  PubMed ID: 2209720   DOI: 10.1016/0014-4827(90)90182-a
5466  Migliaccio G, Migliaccio AR, Kreider BL, Rovera G, Adamson JW.  Selection of lineage-restricted cell lines immortalized at different stages of hematopoietic differentiation from the murine cell line 32D.  J Cell Biol  1989  109(2):833-41  PubMed ID: 2668305   DOI: 10.1083/jcb.109.2.833
5467  Pierce JH, Ruggiero M, Fleming TP, Di Fiore PP, Greenberger JS, Varticovski L, Schlessinger J, Rovera G, Aaronson SA.  Signal transduction through the EGF receptor transfected in IL-3-dependent hematopoietic cells.  Science  1988  239(4840):628-31  PubMed ID: 3257584   DOI: 10.1126/science.3257584
1983  Le Gros, G S, Shackell, P S, Le Gros, J E, Watson, J D  Interleukin 2 regulates the expression of IL 2 receptors on interleukin 3-dependent bone marrow-derived cell lines.  J Immunol  1987  138:478-83  PubMed ID: 3098845  
4924  Tweardy DJ1, Caracciolo D, Valtieri M, Rovera G.  Tumor-derived growth factors that support proliferation and differentiation of normal and leukemic hemopoietic cells.  Ann N Y Acad Sci  1987  511:30-8  PubMed ID: 2830826   DOI: 10.1111/j.1749-6632.1987.tb36235.x
1979  Greenberger, J S, Sakakeeny, M A, Humphries, R K, Eaves, C J, Eckner, R J  Demonstration of permanent factor-dependent multipotential (erythroid/neutrophil/basophil) hematopoietic progenitor cell lines.  Proc Natl Acad Sci U S A  1983  80:2931-5  PubMed ID: 6574462   DOI: 10.1073/pnas.80.10.2931

To topTop
User's Publication
21208  Okamoto K, Imamura T, Tanaka S, Urata T, Yoshida H, Shiba N, Iehara T.  The Nup98::Nsd1 fusion gene induces CD123 expression in 32D cells.  Int J Hematol  2023    PubMed ID: 37173550   DOI: 10.1007/s12185-023-03612-z
14920  Takita M, Tsukahara F, Mishima T, Ieguchi K, Yamada M, Honda H, Maru Y.  Paradoxical counteraction by imatinib against cell death in myeloid progenitor 32D cells expressing p210BCR-ABL  Oncotarget   2018  9(60):31682-31696  PubMed ID: 30167087   DOI: 10.18632/oncotarget.25849
15756  Abe S, Kurata M, Suzuki S, Yamamoto K, Aisaki K, Kanno J, Kitagawa M.  Minichromosome maintenance 2 bound with retroviral Gp70 is localized to cytoplasm and enhances DNA-damage-induced apoptosis  PLoS One  2012  7(6):e40129  PubMed ID: 22768239   DOI: 10.1371/journal.pone.0040129
18982  Tsujimura A, Kiyoi H, Shiotsu Y, Ishikawa Y, Mori Y, Ishida H, Toki T, Ito E, Naoe T.  Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia  Int J Hematol  2010  92(4):624-33  PubMed ID: 20890793   DOI: 10.1007/s12185-010-0692-8
18683  Kiyoi H, Shiotsu Y, Ozeki K, Yamaji S, Kosugi H, Umehara H, Shimizu M, Arai H, Ishii K, Akinaga S, Naoe T.  A novel FLT3 inhibitor FI-700 selectively suppresses the growth of leukemia cells with FLT3 mutations  Clin Cancer Res  2007  13(15 Pt 1):4575-82  PubMed ID: 17671144   DOI: 10.1158/1078-0432.CCR-07-0225
11005  T Kajiguchi, E J Chung, S Lee, A Stine, H Kiyoi, T Naoe, M J Levis, L Neckers, J B Trepel  FLT3 regulates beta-catenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells  Leukemia  2007  21(12):2476-84  PubMed ID: 17851558   DOI: 10.1038/sj.leu.2404923
4884  Kiyoi H, Ohno R, Ueda R, Saito H, Naoe T.  Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain  Oncogene  2002  21(16):2555-63  PubMed ID: 11971190   DOI: 10.1038/sj.onc.1205332
15586  Zhao M, Kiyoi H, Yamamoto Y, Ito M, Towatari M, Omura S, Kitamura T, Ueda R, Saito H, Naoe T.  In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor  Leukemia  2000  14(3):374-8  PubMed ID: 10720129   DOI: 10.1038/sj.leu.2401680

Back Back Return Top Page